Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.303
Neutral
RSI(14)
61.048
Neutral
STOCH(KDJ)(9,3,3)
60.005
Buy
ATR(14)
9.015
Low Volatility
CCI(14)
54.161
Neutral
Williams %R
28.630
Buy
TRIX(12,20)
0.208
Sell
StochRSI(14)
100.000
Buy
Search
Amgen Inc
AMGNAdd to Watchlist
371.510USD
+5.460+1.49%
Close 07-23 16:00（ET）Quotes delayed by 15 min
200.17BMarket Cap
25.65P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+1.49%
5 Days
-0.02%
1 Month
+7.06%
6 Months
+7.76%
Year to Date
+13.50%
1 Year
+20.14%
Key Figures
362.460Open
371.840High
2.93MVolume
25.65P/E TTM
15.85P/E Dynamic
9.800Dividend TTM
0.54%Turnover Ratio
366.050Prev. Close
359.212Low
766.62MTurnover
48.94P/E Static
23.12P/B
2.64%Div Yield TTM
8.58%ROA
391.29052wk High
1.27Volume Ratio
4.09BNet Profit
538.80MShares
14.4856EPS TTM
0.42Beta
101.32%ROE
267.83052wk Low
3.45%Amplitude
71.03%Gross Margin
200.17BMarket Cap
2.82Reward/Risk
1.48%Risk Rate
TradingKey Stock Score of Amgen Inc
Currency: USD Updated: 2026-07-23Key Insights
Amgen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 44 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 363.71.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amgen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
34°C
Very Low
Very High
Negative-
Amgen Inc Highlights
StrengthsRisks
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.37% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.
Fairly Valued
The company’s latest PE is 25.65, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 460.83M shares, increasing 0.49% quarter-over-quarter.
Held by Bill Smead
Star Investor Bill Smead holds 725.23K shares of this stock.
Analyst Rating
Based on
37
analysts
Hold
Current Rating
363.713
Target Price
-0.69%
Upside Space
Amgen Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
37
analysts
Hold
Current Rating
363.713
Target Price
-0.69%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Amgen Inc
AMGN
37
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
Merck & Co Inc
MRK
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
366.850
Buy
MA10
364.324
Buy
MA20
363.934
Buy
MA50
349.431
Buy
MA100
350.429
Buy
MA200
341.111
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amgen Inc Info
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Ticker SymbolAMGN
CompanyAmgen Inc
CEOBradway (Robert A)
Websitehttps://www.amgen.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of Amgen Inc (AMGN)?
The current price of Amgen Inc (AMGN) is 371.51.
What is the symbol of Amgen Inc?
The ticker symbol of Amgen Inc is AMGN.
What is the 52-week high of Amgen Inc?
The 52-week high of Amgen Inc is 391.29.
What is the 52-week low of Amgen Inc?
The 52-week low of Amgen Inc is 267.83.
What is the market capitalization of Amgen Inc?
The market capitalization of Amgen Inc is 200.17B.
Is Amgen Inc (AMGN) currently rated as Buy, Hold, or Sell?
According to analysts, Amgen Inc (AMGN) has an overall rating of signal_hold, with a price target of 363.71.
What is the Earnings Per Share (EPS TTM) of Amgen Inc (AMGN)?
The Earnings Per Share (EPS TTM) of Amgen Inc (AMGN) is 14.33.